D. Boral Capital has issued a new report on ImmunityBio, Inc. (IBRX, Financial) dated July 8, 2025. The analyst Jason Kolbert has decided to maintain his rating and price target for the company.
In the latest update, the current rating for ImmunityBio (IBRX, Financial) remains as "Buy." This is consistent with the prior rating, suggesting continued confidence in the stock's performance.
The price target for ImmunityBio (IBRX, Financial) also remains unchanged at USD 30.00. This reflects the analyst's sustained outlook for the stock's valuation in the market.
As ImmunityBio (IBRX, Financial) continues to trade on the NASDAQ exchange, investors and market watchers may find this reiteration of rating and price target significant in their investment strategies.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 5 analysts, the average target price for ImmunityBio Inc (IBRX, Financial) is $11.40 with a high estimate of $30.00 and a low estimate of $5.00. The average target implies an upside of 319.12% from the current price of $2.72. More detailed estimate data can be found on the ImmunityBio Inc (IBRX) Forecast page.
Based on the consensus recommendation from 5 brokerage firms, ImmunityBio Inc's (IBRX, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
